On the other hand, in the SUSTAIN 6 trial, the effects on plasma lipids of the most powerful of the GLP-1RAs, semaglutide, were not remarkable
Chhaya Makhija, MD, DipABLM Board-Certified Endocrinologist | Lifestyle Medicine Physician | Founder, Unified Endocrine & Diabetes Care Lafayette Fresno California Telemedicine (including Silicon Valley, Palo Alto, Menlo Park, San Francisco, Walnut Creek, Oakland, Sacramento) Watch or Listen to the Full Episode For a deeper dive into the science and real-world clinical nuance:
Patients can try taking their medication with food or starting with a lower dose and gradually increasing it at the discretion of their prescriber
Sixty-three percent of the participants lost at least five percent of their body weight and about 33 percent lost at least 10 percent of their body weight
Average weight loss is usually 1525% of someones total body weight 3 after about one year (compared with about 23% when taking a placebo)
In these cases, therapy can be continued
